China-based baby care products manufacturer Biostime International Holdings Inc. suffered a major loss in the stock markets following news the company is under investigation for possible anticompetitive conduct. According to reports, Biostime shares dropped up to 10 percent – its deepest drop in nearly two years – as the National Development and Reform Commission is looking into the firm for allegations of price-fixing. The case follows just months after Kweichow Moutai and Wuliangye Yibin were both fined by regulators for setting minimum retail prices, say reports.
Featured News
Toast Faces FTC Lawsuit Over Alleged Hidden Fees and Subscription Practices
Oct 29, 2026 by
CPI
Amazon, Uber and Instacart Challenge NYC Delivery Worker Protections in Federal Court
Oct 29, 2026 by
CPI
Wall Street Law Giant Weil Gotshal to Dissolve After Partner Exodus
Oct 29, 2026 by
CPI
DoorDash to Acquire Instacart in $17 Billion Grocery Delivery Deal
Oct 29, 2026 by
CPI
Anthropic Urges California to Give Courts Power to Block High-Risk AI Models
Oct 29, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Exclusive Dealing
Oct 25, 2026 by
CPI
Exclusive Dealing Without Exclusivity: Screening Contracts, Loyalty Rebates, and the Limits of Antitrust Tests
Oct 25, 2026 by
David Martimort & Jérôme Pouyet
When Competition for Exclusivity Raises Prices: Rebates, Pricing Rules, and the Insulin Puzzle
Oct 25, 2026 by
Daniel P. O’Brien & Greg Shaffer
Why Leaving the Door Open Can Be (Much) Worse Than Closing It: Share-Based Requirements, Buyer-Specific Costs, and Foreclosure
Oct 25, 2026 by
Zhijun Chen & Greg Shaffer
Antitrust Chronicle® – EU Merger Guidelines
Oct 19, 2026 by
CPI